2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2279

Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Abstract Number: 405

Dynamics of Transcriptional Signatures from Purified Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
Abstract Number: 657

Dyslipidemia Management Is Insufficient in Psoriatic Arthritis Despite Increased Cardiovascular Morbidity and Mortality
Abstract Number: 2147

Dysphagia in Inflammatory Myositis: A Study of the Structural and Physiologic Changes Resulting in Disordered Swallowing
Abstract Number: 1616

Early and Late Onset Biopsy Proven Lupus Nephritis without Other Associated Autoimmune Diseases: Severity and Long-Term Outcome
Abstract Number: 114

Early Diagnosis and Treatment of RA: Clinical Performance and Economic Outcomes from a Continuing Education Initiative
Abstract Number: 2588

Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV
Abstract Number: 2408

Early Frailty Syndrome in Rhematoid Arthitis: Screening Using the Frail Scale
Abstract Number: 442

Early Treatment with Hydroxychloroquine Is Associated with Better Long-Term Outcomes in a Group of Hispanic Patients with Rheumatoid Arthritis
Abstract Number: 2165

Easily Obtainable Myositis Autoantibody Panel Predictive Factors
Abstract Number: 413

Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA
Abstract Number: 2811

Economic Evaluation of Damage Accrual in a Nationwide Canadian SLE Cohort
Abstract Number: 2925

Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Number: 1759

Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Abstract Number: 478

Ectopic Lymphoid Tissue in the Lung Is Uniquely Associated with the ACPA IgA Isotype Even in Absence of Classifiable RA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].